375 related articles for article (PubMed ID: 28475415)
1. Transthyretin amyloidosis: a phenocopy of hypertrophic cardiomyopathy.
Vermeer AMC; Janssen A; Boorsma PC; Mannens MMAM; Wilde AAM; Christiaans I
Amyloid; 2017 Jun; 24(2):87-91. PubMed ID: 28475415
[TBL] [Abstract][Full Text] [Related]
2. Amyloid heart disease mimicking hypertrophic cardiomyopathy.
Mörner S; Hellman U; Suhr OB; Kazzam E; Waldenström A
J Intern Med; 2005 Sep; 258(3):225-30. PubMed ID: 16115295
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of
Lopes LR; Futema M; Akhtar MM; Lorenzini M; Pittman A; Syrris P; Elliott PM
Amyloid; 2019 Dec; 26(4):243-247. PubMed ID: 31554435
[No Abstract] [Full Text] [Related]
4. Can echocardiography and ECG discriminate hereditary transthyretin V30M amyloidosis from hypertrophic cardiomyopathy?
Gustavsson S; Granåsen G; Grönlund C; Wiklund U; Mörner S; Henein M; Suhr OB; Lindqvist P
Amyloid; 2015; 22(3):163-70. PubMed ID: 26104852
[TBL] [Abstract][Full Text] [Related]
5. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
Coelho T; Maurer MS; Suhr OB
Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
[TBL] [Abstract][Full Text] [Related]
6. Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosis.
Brown EE; Lee YZJ; Halushka MK; Steenbergen C; Johnson NM; Almansa J; Tedford RJ; Cingolani O; Russell SD; Sharma K; Judge DP
Amyloid; 2017 Jun; 24(2):92-95. PubMed ID: 28494620
[TBL] [Abstract][Full Text] [Related]
7. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective.
Rapezzi C; Quarta CC; Obici L; Perfetto F; Longhi S; Salvi F; Biagini E; Lorenzini M; Grigioni F; Leone O; Cappelli F; Palladini G; Rimessi P; Ferlini A; Arpesella G; Pinna AD; Merlini G; Perlini S
Eur Heart J; 2013 Feb; 34(7):520-8. PubMed ID: 22745357
[TBL] [Abstract][Full Text] [Related]
8. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings.
Maia LF; Magalhães R; Freitas J; Taipa R; Pires MM; Osório H; Dias D; Pessegueiro H; Correia M; Coelho T
J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):159-67. PubMed ID: 25091367
[TBL] [Abstract][Full Text] [Related]
9. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G).
Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC
Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244
[TBL] [Abstract][Full Text] [Related]
10. Genetic and clinical characteristics of hereditary transthyretin amyloidosis in endemic and non-endemic areas: experience from a single-referral center in Japan.
Yamashita T; Ueda M; Misumi Y; Masuda T; Nomura T; Tasaki M; Takamatsu K; Sasada K; Obayashi K; Matsui H; Ando Y
J Neurol; 2018 Jan; 265(1):134-140. PubMed ID: 29177547
[TBL] [Abstract][Full Text] [Related]
11. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness.
Damy T; Costes B; Hagège AA; Donal E; Eicher JC; Slama M; Guellich A; Rappeneau S; Gueffet JP; Logeart D; Planté-Bordeneuve V; Bouvaist H; Huttin O; Mulak G; Dubois-Randé JL; Goossens M; Canoui-Poitrine F; Buxbaum JN
Eur Heart J; 2016 Jun; 37(23):1826-34. PubMed ID: 26537620
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR).
Phull P; Sanchorawala V; Connors LH; Doros G; Ruberg FL; Berk JL; Sarosiek S
Amyloid; 2018 Mar; 25(1):62-67. PubMed ID: 29424556
[TBL] [Abstract][Full Text] [Related]
14. Liver transplantation in transthyretin amyloidosis: issues and challenges.
Carvalho A; Rocha A; Lobato L
Liver Transpl; 2015 Mar; 21(3):282-92. PubMed ID: 25482846
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
16. Native T1 and Extracellular Volume in Transthyretin Amyloidosis.
Martinez-Naharro A; Kotecha T; Norrington K; Boldrini M; Rezk T; Quarta C; Treibel TA; Whelan CJ; Knight DS; Kellman P; Ruberg FL; Gillmore JD; Moon JC; Hawkins PN; Fontana M
JACC Cardiovasc Imaging; 2019 May; 12(5):810-819. PubMed ID: 29550324
[TBL] [Abstract][Full Text] [Related]
17. Asp58Ala is the predominant mutation of the TTR gene in Korean patients with hereditary transthyretin-related amyloidosis.
Jang MA; Lee GY; Kim K; Kim SJ; Kim JS; Lee SY; Kim HJ; Jeon ES
Ann Hum Genet; 2015 Mar; 79(2):99-107. PubMed ID: 25644864
[TBL] [Abstract][Full Text] [Related]
18. Disease-associated mutations impacting BC-loop flexibility trigger long-range transthyretin tetramer destabilization and aggregation.
Esperante SA; Varejāo N; Pinheiro F; Sant'Anna R; Luque-Ortega JR; Alfonso C; Sora V; Papaleo E; Rivas G; Reverter D; Ventura S
J Biol Chem; 2021 Sep; 297(3):101039. PubMed ID: 34343569
[TBL] [Abstract][Full Text] [Related]
19. The genetic heterogeneity of hereditary transthyretin amyloidosis in a sample of the Brazilian population.
Lavigne-Moreira C; Marques VD; Gonçalves MVM; de Oliveira MF; Tomaselli PJ; Nunez JC; do Nascimento OJM; Barreira AA; Marques W
J Peripher Nerv Syst; 2018 Jun; 23(2):134-137. PubMed ID: 29520877
[TBL] [Abstract][Full Text] [Related]
20. Transthyretin amyloidosis and the kidney.
Lobato L; Rocha A
Clin J Am Soc Nephrol; 2012 Aug; 7(8):1337-46. PubMed ID: 22537653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
